{"protocolSection": {"identificationModule": {"nctId": "NCT00353873", "orgStudyIdInfo": {"id": "SAM104926"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids", "officialTitle": "A Multicentre, Randomised, Double-blind, Double Dummy, Parallel Group Study to Compare the Salmeterol/Fluticasone Propionate Combination (SeretideTM) at a Dose of 50/100\u00b5g Twice Daily and Fluticasone Propionate (FlixotideTM) at a Dose of 200\u00b5g Twice Daily, Both Delivered Via a Dry Powder Inhaler (DiskusTM) for 12 Weeks in Asthma in Children Aged 4-11 Years Not Controlled by Inhaled Corticosteroids Alone at Medium Dose"}, "statusModule": {"statusVerifiedDate": "2018-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-11-18", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2006-10-26", "type": "ACTUAL"}, "completionDateStruct": {"date": "2006-10-26", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-07-18", "studyFirstSubmitQcDate": "2006-07-18", "studyFirstPostDateStruct": {"date": "2006-07-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-03-13", "resultsFirstSubmitQcDate": "2017-03-13", "resultsFirstPostDateStruct": {"date": "2017-04-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-03-15", "lastUpdatePostDateStruct": {"date": "2018-05-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will compare two treatment strategies (doubling the dose of inhaled steroids or adding a long acting beta2 agonist to the inhaled steroid at the same dose) in children not controlled by inhaled steroid alone at medium dose. The fixed combination SERETIDE 100/50 one inhalation twice daily will be compared to FLIXOTIDE 100 two inhalations twice daily.", "detailedDescription": "A multicentre, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination (SERETIDE\u2122) at a dose of 50/100mcg twice daily and fluticasone propionate (FLIXOTIDE\u2122) at a dose of 200mcg twice daily, both delivered via a dry powder inhaler (DISKUS\u2122) for 12 weeks in asthma in children aged 4-11 years not controlled by inhaled corticosteroids alone at medium dose"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["FLIXOTIDE", "asthmatics children 4-11 years", "SERETIDE", "asthma-control"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 506, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Fluticasone propionate (FLIXOTIDE\u2122)", "type": "ACTIVE_COMPARATOR", "description": "Fluticasone propionate (FLIXOTIDE\u2122) at a dose of 200\u03bcg twice daily", "interventionNames": ["Drug: Fluticasone propionate"]}, {"label": "Fluticasone propionate/salmeterol (SERETIDE\u2122)", "type": "EXPERIMENTAL", "description": "Salmeterol/fluticasone propionate combination (SERETIDE\u2122) at a dose of 50/100\u03bcg twice daily", "interventionNames": ["Drug: Fluticasone propionate/salmeterol"]}], "interventions": [{"type": "DRUG", "name": "Fluticasone propionate", "description": "200\u03bcg twice daily", "armGroupLabels": ["Fluticasone propionate (FLIXOTIDE\u2122)"]}, {"type": "DRUG", "name": "Fluticasone propionate/salmeterol", "description": "50/100\u03bcg twice daily", "armGroupLabels": ["Fluticasone propionate/salmeterol (SERETIDE\u2122)"], "otherNames": ["Fluticasone propionate"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change From Baseline in Morning Peak Expiratory Flow (PEF) Over 12 Weeks in Intent-to-treat (ITT) Population", "description": "PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in electronic diary record card (eDRC), performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using analysis of covariance (ANCOVA) adjusted for baseline PEF, country amalgamation, age, sex and treatment.", "timeFrame": "Baseline; Week 1 up to Week 12"}, {"measure": "Mean Change From Baseline in Morning PEF Over 12 Weeks in Per Protocol (PP) Population", "description": "PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in eDRC, performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using ANCOVA adjusted for baseline PEF, country amalgamation, age, sex and treatment.", "timeFrame": "Baseline; Week 1 up to Week 12"}], "secondaryOutcomes": [{"measure": "Number of Participants Who Achieved 'Totally Controlled' (TC) Asthma", "description": "TC asthma is defined as no daily symptoms, no night-time wakening due to asthma, no exacerbations, no rescue salbutamol/albuterol use, no emergency visits, \\>=80% predicted morning PEF, and no treatment related adverse events enforcing a change in asthma therapy over 7 consecutive days. Number of participants/group who achieved the status of at least TC during the last 8 weeks (wks) of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline pre-bronchodilator Forced Expiratory Volume in one second (FEV1). Asthma control was assessed each week for the last 8 wks of treatment period. Each week was classified as 'TC', 'Well Controlled' (WC), 'Not Controlled' or 'Unevaluable'. A participant was considered to have TC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were TC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.", "timeFrame": "Week 5 up to Week 12"}, {"measure": "Number of Participants Who Achieved WC Asthma", "description": "WC asthma is defined as two or more of symptom score \\>1 only allowed on \\<=2 days/week, rescue salbutamol/albuterol use on \\<=2 days/week and up to a maximum of 4 times per week, \\>=80% predicted morning PEF daily assessed for 7 consecutive days and all the following criteria: no night-time awakening due to asthma, no exacerbations, no emergency visits, no treatment related adverse events enforcing a change in any asthma therapy. Number of participants/group who achieved the status of at least WC during the last 8 wks of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline prebronchodilator FEV1. Each week was classified as 'WC', 'Not Controlled' or 'Unevaluable'. A participant was considered to have WC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were WC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.", "timeFrame": "Week 5 up to Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* A documented clinical history of asthma for a period of at least 6 months.\n* A documented history (within 12 months of Visit 1) of airway reversibility of = 15% based either on Forced expiratory volume (FEV1) or PEF measured pre and post inhalation of 200 mcg salbutamol. (If no documented history of reversibility exists, patients must demonstrate a =15% reversibility at Visit 1).\n* Receiving an inhaled corticosteroid at a medium dose (beclomethasone dipropionate HydroFluoroAlkane (HFA) non fine particle = 400-500 mcg/day or beclomethasone HFA fine particle = 200mcg/day, or budesonide =400 mcg/day or fluticasone = 200 mcg/day (or fluticasone 250mcg/day if subject is taking a 125mcg MDI rather than the 100mcg Diskus), for at least 3 months prior to Visit 1 and at a stable dose for at least 4 weeks prior to Visit 1.\n* Able to use the Mini-Wright peak flow meter and subject or parent/guardian had to be able to record the subject's maximum PEF correctly.\n* Able to perform FEV1 correctly.\n* Subject's guardian/parent able to complete an eDRC on behalf of the subject. The eDRC should be completed by the guardian/parent.\n* Able to use a DISKUS\u2122 correctly.\n* At least one parent(s)/guardian(s) has to give written informed consent to participate in the study.\n\nAt the end of the run-in period (Visit 2), subjects must still meet the criteria for entry into the run-in period and also have:\n\n* not achieved the criteria for the 'Well-controlled' asthma during two or more of the 4 weeks prior to Visit 2.\n\nExclusion criteria:\n\n* Female subjects who have reached menarche.\n* Received any investigational study medication in the 4 weeks prior to Visit 1.\n* Experienced a respiratory tract infection in the 4 weeks prior to Visit 1.\n* Experienced an acute asthma exacerbation requiring emergency room treatment within 4 weeks or hospitalisation within 12 weeks of Visit 1.\n* Any use of oral/parenteral or depot corticosteroid within 12 weeks of Visit 1.\n* Any use of long-acting inhaled beta2-agonists or oral beta2-agonists within 4 weeks of Visit 1.\n* Any use of leukotriene antagonists or theophyllines within 4 weeks of Visit 1.\n* Any known clinical or laboratory evidence of a serious uncontrolled disease (including serious psychological disorders) which is, in the opinion of the investigator, likely to interfere with the study.\n* Subjects with a known or suspected hypersensitivity to inhaled corticosteroids, beta2-agonists, or any components of the formulations (e.g. lactose)\n* A relative of any of the site staff, including the investigator or study co-coordinator.\n* Has previously been entered into this study.\n\nSubjects will be excluded from participating in the treatment period of the study if the following occurred during the run-in period:\n\n* Pre-bronchodilator FEV1 \\<60% (assuming that measurement was correctly performed).\n* Any change in asthma medication (excluding use of prophylactic study specific salbutamol for prevention of asthma symptoms due to exercise).\n* Respiratory tract infection or asthma exacerbation.\n* Use of oral, parenteral or depot corticosteroids.\n* Emergency visit due to asthma.\n* Non-compliance with the completion of the eDRC (i.e. during the 4 week period between visits, non compliance is defined as less than 5 days of completed data within any one week for four weeks - subjects must complete at least 5 days a week for the entire run-in period).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "4 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Brugge", "zip": "8000", "country": "Belgium", "geoPoint": {"lat": 51.20892, "lon": 3.22424}}, {"facility": "GSK Investigational Site", "city": "Brussel", "zip": "1090", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "GSK Investigational Site", "city": "Edegem", "zip": "2650", "country": "Belgium", "geoPoint": {"lat": 51.15662, "lon": 4.44504}}, {"facility": "GSK Investigational Site", "city": "Gent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "GSK Investigational Site", "city": "Leuven", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "GSK Investigational Site", "city": "Aalborg", "zip": "9000", "country": "Denmark", "geoPoint": {"lat": 57.048, "lon": 9.9187}}, {"facility": "GSK Investigational Site", "city": "Odense", "zip": "5000 Odense C", "country": "Denmark", "geoPoint": {"lat": 55.39594, "lon": 10.38831}}, {"facility": "GSK Investigational Site", "city": "Essey les Nancy", "zip": "54270", "country": "France", "geoPoint": {"lat": 48.70179, "lon": 6.22425}}, {"facility": "GSK Investigational Site", "city": "Grasse", "zip": "06130", "country": "France", "geoPoint": {"lat": 43.66667, "lon": 6.91667}}, {"facility": "GSK Investigational Site", "city": "Laon", "zip": "02000", "country": "France", "geoPoint": {"lat": 49.56667, "lon": 3.61667}}, {"facility": "GSK Investigational Site", "city": "Nimes", "zip": "30900", "country": "France", "geoPoint": {"lat": 43.83333, "lon": 4.35}}, {"facility": "GSK Investigational Site", "city": "Oyonnax", "zip": "01100", "country": "France", "geoPoint": {"lat": 46.25917, "lon": 5.65727}}, {"facility": "GSK Investigational Site", "city": "Paris cedex 15", "zip": "75730", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "GSK Investigational Site", "city": "Paris", "zip": "75019", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "GSK Investigational Site", "city": "Rouen Cedex", "zip": "76031", "country": "France", "geoPoint": {"lat": 49.44313, "lon": 1.09932}}, {"facility": "GSK Investigational Site", "city": "Rouen", "zip": "76000", "country": "France", "geoPoint": {"lat": 49.44313, "lon": 1.09932}}, {"facility": "GSK Investigational Site", "city": "Saint Michel", "zip": "16470", "country": "France", "geoPoint": {"lat": 49.91952, "lon": 4.13278}}, {"facility": "GSK Investigational Site", "city": "Tours Cedex 1", "zip": "37000", "country": "France", "geoPoint": {"lat": 47.38333, "lon": 0.68333}}, {"facility": "GSK Investigational Site", "city": "Vaux En Velin", "zip": "69120", "country": "France"}, {"facility": "GSK Investigational Site", "city": "Villejuif", "zip": "94800", "country": "France", "geoPoint": {"lat": 48.7939, "lon": 2.35992}}, {"facility": "GSK Investigational Site", "city": "Napoli", "state": "Campania", "zip": "80138", "country": "Italy", "geoPoint": {"lat": 40.85216, "lon": 14.26811}}, {"facility": "GSK Investigational Site", "city": "Foggia", "state": "Puglia", "zip": "71100", "country": "Italy", "geoPoint": {"lat": 41.45845, "lon": 15.55188}}, {"facility": "GSK Investigational Site", "city": "Palermo", "state": "Sicilia", "zip": "90127", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "GSK Investigational Site", "city": "Perugia", "state": "Umbria", "zip": "06122", "country": "Italy", "geoPoint": {"lat": 43.1122, "lon": 12.38878}}, {"facility": "GSK Investigational Site", "city": "Daugavpils", "zip": "LV5403", "country": "Latvia", "geoPoint": {"lat": 55.88333, "lon": 26.53333}}, {"facility": "GSK Investigational Site", "city": "Riga", "zip": "LV 1004", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "GSK Investigational Site", "city": "Riga", "zip": "LV 1064", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "GSK Investigational Site", "city": "Kaunas", "zip": "LT-50425", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "GSK Investigational Site", "city": "Taurage", "zip": "LT-72214", "country": "Lithuania", "geoPoint": {"lat": 55.25222, "lon": 22.28972}}, {"facility": "GSK Investigational Site", "city": "Vilnius", "zip": "LT-10207", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "GSK Investigational Site", "city": "Almere", "zip": "1315 RA", "country": "Netherlands", "geoPoint": {"lat": 52.37535, "lon": 5.25295}}, {"facility": "GSK Investigational Site", "city": "Beek En Donk", "zip": "5741 CG", "country": "Netherlands", "geoPoint": {"lat": 51.54158, "lon": 5.62603}}, {"facility": "GSK Investigational Site", "city": "Den Haag", "zip": "2517 EW", "country": "Netherlands", "geoPoint": {"lat": 52.07667, "lon": 4.29861}}, {"facility": "GSK Investigational Site", "city": "Deurne", "zip": "5751 XJ", "country": "Netherlands", "geoPoint": {"lat": 51.46, "lon": 5.79722}}, {"facility": "GSK Investigational Site", "city": "Emmen", "zip": "7824 AA", "country": "Netherlands", "geoPoint": {"lat": 52.77917, "lon": 6.90694}}, {"facility": "GSK Investigational Site", "city": "Ermelo", "zip": "3851 EX", "country": "Netherlands", "geoPoint": {"lat": 52.29833, "lon": 5.62222}}, {"facility": "GSK Investigational Site", "city": "Nieuwegein", "zip": "3435 CM", "country": "Netherlands", "geoPoint": {"lat": 52.02917, "lon": 5.08056}}, {"facility": "GSK Investigational Site", "city": "Spijkenisse", "zip": "3207 NB", "country": "Netherlands", "geoPoint": {"lat": 51.845, "lon": 4.32917}}, {"facility": "GSK Investigational Site", "city": "Tiel", "zip": "4002 WP", "country": "Netherlands", "geoPoint": {"lat": 51.88667, "lon": 5.42917}}, {"facility": "GSK Investigational Site", "city": "Woerden", "zip": "3447 GN", "country": "Netherlands", "geoPoint": {"lat": 52.085, "lon": 4.88333}}, {"facility": "GSK Investigational Site", "city": "Drammen", "zip": "N-3018", "country": "Norway", "geoPoint": {"lat": 59.74389, "lon": 10.20449}}, {"facility": "GSK Investigational Site", "city": "Kongsvinger", "zip": "N-2226", "country": "Norway", "geoPoint": {"lat": 60.19049, "lon": 11.99772}}, {"facility": "GSK Investigational Site", "city": "Oslo", "zip": "N-0855", "country": "Norway", "geoPoint": {"lat": 59.91273, "lon": 10.74609}}, {"facility": "GSK Investigational Site", "city": "Bialystok", "zip": "15-274", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "GSK Investigational Site", "city": "Krakow", "zip": "31-159", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "GSK Investigational Site", "city": "Lodz", "zip": "93-513", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "GSK Investigational Site", "city": "Lublin", "zip": "20-093", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "GSK Investigational Site", "city": "Krasnoyarsk", "zip": "660022", "country": "Russian Federation", "geoPoint": {"lat": 56.01839, "lon": 92.86717}}, {"facility": "GSK Investigational Site", "city": "Moscow", "zip": "115446", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "GSK Investigational Site", "city": "Moscow", "zip": "119435", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "GSK Investigational Site", "city": "Moscow", "zip": "119991", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "GSK Investigational Site", "city": "Novokuznetsk", "zip": "654063", "country": "Russian Federation", "geoPoint": {"lat": 53.7557, "lon": 87.1099}}, {"facility": "GSK Investigational Site", "city": "Novosibirsk", "zip": "630099", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "GSK Investigational Site", "city": "St'Petersburg", "zip": "191144", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GSK Investigational Site", "city": "Syktyvkar", "zip": "167011", "country": "Russian Federation", "geoPoint": {"lat": 61.67642, "lon": 50.80994}}, {"facility": "GSK Investigational Site", "city": "Tomsk", "zip": "634 050", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "GSK Investigational Site", "city": "Almeria", "zip": "04009", "country": "Spain", "geoPoint": {"lat": 36.83814, "lon": -2.45974}}, {"facility": "GSK Investigational Site", "city": "Barcelona", "zip": "08035", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "GSK Investigational Site", "city": "Madrid", "zip": "28006", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "GSK Investigational Site", "city": "Madrid", "zip": "28009", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "GSK Investigational Site", "city": "San Sebasti\u00e1n", "zip": "20014", "country": "Spain", "geoPoint": {"lat": 43.31283, "lon": -1.97499}}, {"facility": "GSK Investigational Site", "city": "Sevilla", "zip": "41071", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "GSK Investigational Site", "city": "Sollentuna", "zip": "SE-191 24", "country": "Sweden", "geoPoint": {"lat": 59.42804, "lon": 17.95093}}, {"facility": "GSK Investigational Site", "city": "Stockholm", "zip": "SE-141 86", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "GSK Investigational Site", "city": "Stockholm", "zip": "SE-171 76", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "SAM104926", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "SAM104926", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "SAM104926", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "SAM104926", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "SAM104926", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "SAM104926", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "SAM104926", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 584 participants were screened and entered into a 4-week run-in period receiving fluticasone propionate (FP) 100 microgram (mcg) dry powder inhaler (DISKUS) twice-daily (BD) and inhaled salbutamol as required. The number of participants randomized was 321 and 303 participants received investigational product post randomization.", "recruitmentDetails": "The study was conducted at 46 sites in 12 countries: Belgium (4), Denmark (1), France (8), Italy (3), Latvia (3), Lithuania (3), the Netherlands (6), Norway (1), Poland (4), Russian Federation (9), Spain (3) and Sweden (1) from 18 November 2005 to 26 October 2006.", "groups": [{"id": "FG000", "title": "FP 200 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (FP 100 mcg) and dry powder inhaler B (FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation metered dose inhaler (MDI) to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms."}, {"id": "FG001", "title": "Salmeterol/Fluticasone Propionate (SFC) 50/100 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (SFC 50/100 mcg) and dry powder inhaler B (placebo for FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation MDI to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "153"}, {"groupId": "FG001", "numSubjects": "150"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "147"}, {"groupId": "FG001", "numSubjects": "147"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Exacerbation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "FP 200 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (FP 100 mcg) and dry powder inhaler B (FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation MDI to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms."}, {"id": "BG001", "title": "SFC 50/100 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (SFC 50/100 mcg) and dry powder inhaler B (placebo for FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation MDI to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "153"}, {"groupId": "BG001", "value": "150"}, {"groupId": "BG002", "value": "303"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.0", "spread": "2.01"}, {"groupId": "BG001", "value": "8.1", "spread": "2.00"}, {"groupId": "BG002", "value": "8.0", "spread": "2.00"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "108"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "98"}, {"groupId": "BG001", "value": "97"}, {"groupId": "BG002", "value": "195"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}]}, {"title": "White - Arabic/North African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}]}, {"title": "White - White/Caucasian/European Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "146"}, {"groupId": "BG001", "value": "144"}, {"groupId": "BG002", "value": "290"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change From Baseline in Morning Peak Expiratory Flow (PEF) Over 12 Weeks in Intent-to-treat (ITT) Population", "description": "PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in electronic diary record card (eDRC), performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using analysis of covariance (ANCOVA) adjusted for baseline PEF, country amalgamation, age, sex and treatment.", "populationDescription": "ITT Population: All participants randomized to treatment who received at least one dose of randomized study medication. Only participants with analyzable data at the indicated time point were assessed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters/Minute (L/min)", "timeFrame": "Baseline; Week 1 up to Week 12", "groups": [{"id": "OG000", "title": "FP 200 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (FP 100 mcg) and dry powder inhaler B (FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation MDI to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms."}, {"id": "OG001", "title": "SFC 50/100 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (SFC 50/100 mcg) and dry powder inhaler B (placebo for FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation MDI to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "152"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19.3", "spread": "2.12"}, {"groupId": "OG001", "value": "26.9", "spread": "2.13"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Non-inferiority was tested using a one-sided significance level of 2.5%. If the lower confidence interval for the difference SFC-FP falls above -12 L/min the once daily SFC treatment combination was deemed to be statistically non-inferior. In the event that the lower confidence limit (2.5% 1-sided significance) exceeded 0, and using a separate closed testing procedure, superiority could be established.", "pValue": "0.012", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "7.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.7", "ciUpperLimit": "13.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.01"}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Morning PEF Over 12 Weeks in Per Protocol (PP) Population", "description": "PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in eDRC, performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using ANCOVA adjusted for baseline PEF, country amalgamation, age, sex and treatment.", "populationDescription": "PP Population: All participants in the ITT Population who did not have any protocol violations which could impact treatment effect. Only participants with analyzable data at the indicated time point were assessed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "Baseline; Week 1 up to Week 12", "groups": [{"id": "OG000", "title": "FP 200 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (FP 100 mcg) and dry powder inhaler B (FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation MDI to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms."}, {"id": "OG001", "title": "SFC 50/100 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (SFC 50/100 mcg) and dry powder inhaler B (placebo for FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation MDI to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18.4", "spread": "2.14"}, {"groupId": "OG001", "value": "27.7", "spread": "2.21"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Non-inferiority was tested using a one-sided significance level of 2.5%. If the lower confidence interval for the difference SFC-FP falls above -12 L/min the once daily SFC treatment combination was deemed to be statistically non-inferior. In the event that the lower confidence limit (2.5% 1-sided significance) exceeded 0, and using a separate closed testing procedure, superiority could be established.", "pValue": "0.003", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "9.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.2", "ciUpperLimit": "15.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.08"}]}, {"type": "SECONDARY", "title": "Number of Participants Who Achieved 'Totally Controlled' (TC) Asthma", "description": "TC asthma is defined as no daily symptoms, no night-time wakening due to asthma, no exacerbations, no rescue salbutamol/albuterol use, no emergency visits, \\>=80% predicted morning PEF, and no treatment related adverse events enforcing a change in asthma therapy over 7 consecutive days. Number of participants/group who achieved the status of at least TC during the last 8 weeks (wks) of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline pre-bronchodilator Forced Expiratory Volume in one second (FEV1). Asthma control was assessed each week for the last 8 wks of treatment period. Each week was classified as 'TC', 'Well Controlled' (WC), 'Not Controlled' or 'Unevaluable'. A participant was considered to have TC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were TC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.", "populationDescription": "ITT Population. Only participants with analyzable data at the indicated time point were assessed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 5 up to Week 12", "groups": [{"id": "OG000", "title": "FP 200 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (FP 100 mcg) and dry powder inhaler B (FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation MDI to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms."}, {"id": "OG001", "title": "SFC 50/100 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (SFC 50/100 mcg) and dry powder inhaler B (placebo for FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation MDI to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "152"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.389", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.7", "ciUpperLimit": "2.4"}]}, {"type": "SECONDARY", "title": "Number of Participants Who Achieved WC Asthma", "description": "WC asthma is defined as two or more of symptom score \\>1 only allowed on \\<=2 days/week, rescue salbutamol/albuterol use on \\<=2 days/week and up to a maximum of 4 times per week, \\>=80% predicted morning PEF daily assessed for 7 consecutive days and all the following criteria: no night-time awakening due to asthma, no exacerbations, no emergency visits, no treatment related adverse events enforcing a change in any asthma therapy. Number of participants/group who achieved the status of at least WC during the last 8 wks of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline prebronchodilator FEV1. Each week was classified as 'WC', 'Not Controlled' or 'Unevaluable'. A participant was considered to have WC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were WC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.", "populationDescription": "ITT Population. Only participants with analyzable data at the indicated time point were assessed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 5 up to Week 12", "groups": [{"id": "OG000", "title": "FP 200 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (FP 100 mcg) and dry powder inhaler B (FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation MDI to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms."}, {"id": "OG001", "title": "SFC 50/100 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (SFC 50/100 mcg) and dry powder inhaler B (placebo for FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation MDI to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "152"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "65"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.535", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.7", "ciUpperLimit": "1.9"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Serious adverse events and non-serious adverse events were collected from the first day of treatment until the last day of treatment (up to 12 weeks).", "description": "On-treatment serious adverse events and non-serious adverse events were reported for ITT Population.", "eventGroups": [{"id": "EG000", "title": "FP 200 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (FP 100 mcg) and dry powder inhaler B (FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation metered dose inhaler (MDI) to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms.", "seriousNumAffected": 3, "seriousNumAtRisk": 153, "otherNumAffected": 61, "otherNumAtRisk": 153}, {"id": "EG001", "title": "SFC 50/100 mcg BD", "description": "Participants received one inhalation from dry powder inhaler A (SFC 50/100 mcg) and dry powder inhaler B (placebo for FP 100 mcg) BD, in the morning and evening for 12 weeks. Participants were provided salbutamol 100 mcg per actuation MDI to be used as needed throughout the study, for prevention of exercise induced asthma and symptomatic relief from asthma symptoms.", "seriousNumAffected": 3, "seriousNumAtRisk": 150, "otherNumAffected": 55, "otherNumAtRisk": 150}], "seriousEvents": [{"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 150}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 150}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 150}]}, {"term": "Laryngotracheitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 150}]}, {"term": "Wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 150}]}], "otherEvents": [{"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 150}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 150}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 27, "numAtRisk": 150}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 150}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 150}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 150}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}